Project summary
Therapeutic targets to inhibit sympathetic nervous system activation.
What is the issue for NSW?
The sympathetic nervous system (SNS) is a key regulator of cardiovascular (CV) and metabolic function. Targeting the SNS to inhibit its activation therefore has great potential to improve both CV and metabolic health.
What does the research aim to do and how?
A pioneer in exploring potential therapeutic targets to inhibit SNS activation, Professor Schlaich currently leads a first-in-human study to assess the BP lowering effect of transluminal ablation of the carotid body (CB) and is involved in a first-in-human study of catheter-based hepatic denervation to improve glucose metabolism in patients with T2DM. Mechanistically, he has demonstrated a link between SNS activation and other drivers of CV and metabolic disease such as the immune system14,15.
This work provides the foundation for the proposed highly innovative research program. Prof Schlaich will utilize the University of Sydney’s resources to perform further studies and translate these novel therapeutic approaches and technologies into clinical practice. The program’s 5 projects are highly likely to result in significant knowledge gain and changes in clinical practice within 5 years.